

Pharmaceutical Biotechnology • Volume 12

# Membrane Transporters as Drug Targets

Edited by  
Gordon L. Amidon and  
Wolfgang Sadée

# Membrane Transporters as Drug Targets

Edited by

**Gordon L. Amidon**

University of Michigan  
Ann Arbor, Michigan

and

**Wolfgang Sadée**

University of California, San Francisco  
San Francisco, California



Y752011

**Kluwer Academic/Plenum Publishers**  
New York, Boston, Dordrecht, London, Moscow

Membrane transporters as drug targets / edited by Gordon L. Amidon and Wolfgang Sadee.

p. cm. -- (Pharmaceutical biotechnology ; v. 12)

Includes bibliographical references and index.

ISBN 0-306-46094-7

1. Drug targeting. 2. Drugs--Physiological transport. 3. Carrier proteins. 4. Drug carriers (Pharmacy) I. Amidon, Gordon L. II. Series.

[DNLM: 1. Membrane Proteins--physiology. 2. Biological Transport--physiology. 3. Carrier Proteins--physiology. 4. Drug Carriers. 5. Receptors, Drug. W1 PH151N v.12 1999]

RM301.65.M45 1999

615'.7--dc21

DNLM/DLC

for Library of Congress

99-37278

CIP

ISBN: 0-306-46094-7

© 1999 Kluwer Academic/Plenum Publishers, New York  
233 Spring Street, New York, N.Y. 10013

10 9 8 7 6 5 4 3 2 1

A C.I.P. record for this book is available from the Library of Congress

All rights reserved

No part of this book may be reproduced, stored in a retrieval system, or transmitted in any form or by any means, electronic, mechanical, photocopying, microfilming, recording, or otherwise, without written permission from the Publisher

Printed in the United States of America

## Contributors

*David H. Alpers* • Gastroenterology Division, Washington University School of Medicine, St. Louis, Missouri 63110

*Gordon L. Amidon* • College of Pharmacy, University of Michigan, Ann Arbor, Michigan 48109-1065

*Matthew J. Androlewicz* • Immunology Program, H. Lee Moffitt Cancer Center and Research Institute, and Department of Biochemistry and Molecular Biology, University of South Florida College of Medicine, Tampa, Florida 33612

*Kenneth L. Audus* • Department of Pharmaceutical Chemistry, School of Pharmacy, University of Kansas, Lawrence, Kansas 66047

*Stephen A. Baldwin* • School of Biochemistry and Molecular Biology, University of Leeds, Leeds, United Kingdom

*Jürg Biber* • Physiological Institute, University of Zurich, CH-8057, Zurich, Switzerland

*Miguel A. Cabrita* • Molecular Biology of Membranes Group, Membrane Transport Research Group, and Department of Biochemistry, University of Alberta, and Department of Experimental Oncology, Cross Cancer Institute, Edmonton, Alberta, Canada

*Carol E. Cass* • Molecular Biology of Membranes Group, Membrane Transport Research Group, and Departments of Biochemistry and Oncology, Uni-

versity of Alberta, and Department of Experimental Oncology, Cross Cancer Institute, Edmonton, Alberta, Canada

*Ellen I. Closs* • Department of Pharmacology, Johannes Gutenberg University, D-55101 Mainz, Germany

*Mark J. Dresser* • Department of Biopharmaceutical Sciences, University of California San Francisco, San Francisco, California 94143

*Ian Forster* • Physiological Institute, University of Zurich, CH-8057, Zurich, Switzerland

*Kathleen M. Giacomini* • Department of Biopharmaceutical Sciences, University of California San Francisco, San Francisco, California 94143

*Gwyn W. Gould* • Division of Biochemistry and Molecular Biology, Institute of Biomedical and Life Sciences, University of Glasgow, Glasgow G12 8QQ, Scotland

*Petra Gräf* • Department of Pharmacology, Johannes Gutenberg University, D-55101 Mainz, Germany

*Kathryn A. Graham* • Molecular Biology of Membranes Group, Membrane Transport Research Group, and Department of Oncology, University of Alberta, and Department of Experimental Oncology, Cross Cancer Institute, Edmonton, Alberta, Canada

*Richard C. Graul* • Departments of Biopharmaceutical Sciences and Pharmaceutical Chemistry, School of Pharmacy, University of California San Francisco, San Francisco, California 94143-0446

*Mark Griffiths* • School of Biochemistry and Molecular Biology, University of Leeds, Leeds, United Kingdom

*Hyo-kyung Han* • College of Pharmacy, University of Michigan, Ann Arbor, Michigan 48109-1065

*Guido J. E. J. Hooiveld* • Department of Pharmacokinetics and Drug Delivery, Groningen University Institute for Drug Exploration (GUIDE), Groningen, The Netherlands, and Department of Gastroenterology and Hepatology, University Hospital, Groningen, The Netherlands

*Ken-ichi Inui* • Department of Pharmacy, Kyoto University Hospital, Sakyo-ku, Kyoto 606-8507, Japan

*Peter L. M. Jansen* • Department of Gastroenterology and Hepatology, University Hospital, Groningen, The Netherlands

*Lori L. Jennings* • Molecular Biology of Membranes Group, Membrane Transport Research Group, and Department of Oncology, University of Alberta, and Department of Experimental Oncology, Cross Cancer Institute, Edmonton, Alberta, Canada

*Vashti G. Lacaille* • Immunology Program, H. Lee Moffitt Cancer Center and Research Institute, and Department of Biochemistry and Molecular Biology, University of South Florida College of Medicine, Tampa, Florida 33612

*Alan Y. Lee* • Departments of Biopharmaceutical Sciences and Pharmaceutical Chemistry, School of Pharmacy, University of California San Francisco, San Francisco, California 94143-0446

*John R. Mackey* • Department of Oncology, University of Alberta, and Departments of Experimental Oncology and Medicine, Cross Cancer Institute, Edmonton, Alberta, Canada

*Dirk K. F. Meijer* • Department of Pharmacokinetics and Drug Delivery, Groningen University Institute for Drug Exploration (GUIDE), Groningen, The Netherlands

*Michael Müller* • Department of Gastroenterology and Hepatology, University Hospital, Groningen, The Netherlands

*Heini Murer* • Physiological Institute, University of Zurich, CH-8057 Zurich, Switzerland

*Amy M. L. Ng* • Membrane Transport Research Group and Department of Physiology, University of Alberta, Edmonton, Alberta, Canada

*Doo-Man Oh* • Department of Pharmacokinetics, Dynamics, and Metabolism, Parke-Davis Pharmaceutical Research Division, Warner-Lambert Company, Ann Arbor, Michigan 48105

*Mabel W. L. Ritzel* • Membrane Transport Research Group and Department of Physiology, University of Alberta, Edmonton, Alberta, Canada



*Bertrand Rochat* • Department of Pharmaceutical Chemistry, School of Pharmacy, University of Kansas, Lawrence, Kansas 66047

*Gregory J. Russell-Jones* • C/- Biotech Australia Pty Ltd, Roseville, NSW, 2069 Australia

*Wolfgang Sadée* • Departments of Biopharmaceutical Sciences and Pharmaceutical Chemistry, School of Pharmacy, University of California San Francisco, San Francisco, California 94143-0446

*Michael J. Seatter* • Division of Biochemistry and Molecular Biology, Institute of Biomedical and Life Sciences, University of Glasgow, Glasgow G12 8QQ, Scotland

*Jeffrey A. Silverman* • AvMax, Inc., South San Francisco, CA 94080

*Johan W. Smit* • Department of Pharmacokinetics and Drug Delivery, Groningen University Institute for Drug Exploration (GUIDE), Groningen, The Netherlands; present address: Division of Experimental Therapy, The Netherlands Cancer Institute, Amsterdam, The Netherlands

*Yuichi Sugiyama* • Graduate School of Pharmaceutical Sciences, University of Tokyo, Hongo, Bunkyo-ku, Tokyo 113-0033, Japan

*Hiroshi Suzuki* • Graduate School of Pharmaceutical Sciences, University of Tokyo, Hongo, Bunkyo-ku, Tokyo 113-0033, Japan

*Ikumi Tamai* • Department of Pharmacobio-Dynamics, Faculty of Pharmaceutical Sciences, Kanazawa University, 13-1 Takara-machi, Kanazawa 920-0934, Japan

*Tomohiro Terada* • Department of Pharmacy, Kyoto University Hospital, Sakyo-ku, Kyoto 606-8507, Japan

*Akira Tsuji* • Department of Pharmacobio-Dynamics, Faculty of Pharmaceutical Sciences, Kanazawa University, 13-1 Takara-michi, Kanazawa 920-0934, Japan

*Karl Julius Ullrich* • Max Planck Institute for Biophysics, 60596 Frankfurt am Main, Germany

*Jessica E. van Montfoort* • Department of Pharmacokinetics and Drug Deliv-

ery, Groningen University Institute for Drug Exploration (GUIDE), Groningen, The Netherlands, and Department of Gastroenterology and Hepatology, University Hospital, Groningen, The Netherlands

*Mark F. Vickers* • Molecular Biology of Membranes Group, Membrane Transport Research Group, and Department of Biochemistry, University of Alberta, and Department of Experimental Oncology, Cross Cancer Institute, Edmonton, Alberta, Canada

*Sylvia Y. M. Yao* • Membrane Transport Research Group and Department of Physiology, University of Alberta, Edmonton, Alberta, Canada

*James D. Young* • Membrane Transport Research Group and Department of Physiology, University of Alberta, Edmonton, Alberta, Canada

*Lei Zhang* • Department of Biopharmaceutical Sciences, University of California San Francisco, San Francisco, California 94143



## Preface to the Series

A major challenge confronting pharmaceutical scientists in the future will be to design successful dosage forms for the next generation of drugs. Many of these drugs will be complex polymers of amino acids (e.g., peptides, proteins), nucleosides (e.g., antisense molecules), carbohydrates (e.g., polysaccharides), or complex lipids.

Through rational drug design, synthetic medicinal chemists are preparing very potent and very specific peptides and antisense drug candidates. These molecules are being developed with molecular characteristics that permit optimal interaction with the specific macromolecules (e.g., receptors, enzymes, RNA, DNA) that mediate their therapeutic effects. Rational drug design does not necessarily mean rational drug delivery, however, which strives to incorporate into a molecule the molecular properties necessary for optimal transfer between the point of administration and the pharmacological target site in the body.

Like rational drug design, molecular biology is having a significant impact on the pharmaceutical industry. For the first time, it is possible to produce large quantities of highly pure proteins, polysaccharides, and lipids for possible pharmaceutical applications. Like peptides and antisense molecules, the design of successful dosage forms for these complex biotechnology products represents a major challenge to pharmaceutical scientists.

Development of an acceptable drug dosage form is a complex process requiring strong interactions between scientists from many different divisions in a pharmaceutical company, including discovery, development, and manufacturing. The series editor, the editors of the individual volumes, and the publisher hope that this new series will be particularly helpful to scientists in the development areas of a pharmaceutical company, (e.g., drug metabolism, toxicology, pharmacokinetics and pharmacodynamics, drug delivery, preformulation, formulation, and physical and analytical chemistry). In addition, we hope this series will help to

build bridges between the development scientists and scientists in discovery (e.g., medicinal chemistry, pharmacology, immunology, cell biology, molecular biology) and in manufacturing (e.g., process chemistry, engineering). The design of successful dosage forms for the next generation of drugs will require not only a high level of expertise by individual scientists, but also a high degree of interaction between scientists in these different divisions of a pharmaceutical company.

Finally, everyone involved with this series hopes that these volumes will also be useful to the educators who are training the next generation of pharmaceutical scientists. In addition to having a high level of expertise in their respective disciplines, these young scientists will need to have the scientific skills necessary to communicate with their peers in other scientific disciplines.

RONALD T. BORCHARDT  
Series Editor

## Preface

This monograph appears at a propitious time. Researchers from molecular biology, human genetics, bioinformatics, and drug development are converging on an integrated approach to studying membrane transporters. With the recent cloning of numerous transporter genes, substrate translocation across membranes is coming into focus at the molecular level. Moreover, with the complete sequencing of entire genomes, we have a first glimpse at not just a few transporter families, but all transporters in a living organism. This wealth of information is bound to change research directions by broadening our general understanding of the physiological role of transporters, their diversity and redundancy within an organism, and differences among various species. Soon, the entire human genome will be sequenced, and we will then deal with a large, but finite number of transporter genes. One might estimate that there are 2000–4000 human transporter/ion exchanger genes. Methodology to deal with such large gene numbers is now available, and a genomics-driven approach to transporter mechanisms and functions will likely transform this field in the near future. The chapters in this book already presage this transition, by including not just single transporters, but entire transporter gene families. Yet, only a fraction of all human transporters has been cloned, and much more work needs to be done.

While this book focuses on the interaction of drugs with transporters, scientists from various disciplines have contributed chapters providing in-depth analyses of the physiology, molecular biology, and regulation of select transporter families. Moreover, scientists traditionally involved with drug development have increasingly incorporated molecular biology into their work, a crucial step in understanding the complexities of drug absorption, distribution, and targeting in the body. This book demonstrates that these diverse disciplines are no longer separate entities, and that the boundaries among them have blurred. A physiologist needs to be concerned with the relevance of a transport function to drug targeting, where-

as a scientist in drug development must delve into the molecular biology of the many transporters that could determine efficacy and, hence, clinical success of a new drug entity. Juxtaposing these various views of transporters in this book provides insight into the current state of development of this field, providing a reliable beacon for future developments. We therefore think that this monograph will remain topical for some time to come.

The book is divided into three main portions, the first dealing with background information, including drug transport methodologies and transporter classification, the second providing an integral pharmaceutical view of drug transport in several organs of the body, and the third focusing on individual transporter families. This last portion is not meant to be all-inclusive, but rather to provide examples of well-studied transporter families, presented by prominent scientists in different disciplines. In the future we intend to revisit this topic, and include additional large transporter families, some of which double as drug receptors *per se*, rather than drug targeting devices, e.g., the neurotransmitter transporters. Moreover, the ion exchangers, structurally related to transporters, interact with many drugs, and these are also not included here.

Given the number and complexity of human transporter families, and the importance they have in drug action, we can anticipate rapid expansion of this field and of the number of investigators involved in it. This will also lead to increasing focus on pharmacogenetics, i.e., the study of interindividual differences at the genetic level. Already a central theme in drug metabolism, particularly with focus on genetic polymorphism of the cytochrome P450 enzymes, virtually nothing is known about genetic polymorphism of drug transporters. For example, the intestinal H<sup>+</sup>/dipeptide transporter appears to play a role in the oral absorption of cephalosporins, but we have not yet even tested whether some patients carry mutations that abrogate cephalosporin transport. This is certainly likely, the main question being what fraction of the population would have such genetic defects. We think that the information provided in this book will form the basis of addressing the pharmacogenetics of transporters in general. Seen from a genomics perspective, with an all-inclusive approach for all possible transporters, this might rather be called the pharmacogenomics of drug transporters. Much can be gained by understanding the entirety of human transported genes, their relevance to any chosen drug, and the genetic variations distributed throughout the patient population. This book advances the current state of the transporter field toward these goals.

GORDON L. AMIDON  
WOLFGANG SADÉE

# Contents

## Chapter 1

<b>Overview of Membrane Transport</b> .....	<b>1</b>
<i>Doo-Man Oh and Gordon L. Amidon</i>	
1. Introduction .....	1
2. Modes of Membrane Transport .....	3
2.1. Passive Diffusion .....	5
2.2. Ion Channels .....	6
2.3. Facilitated Diffusion .....	9
2.4. Active Transporters .....	10
2.5. Secondary Active Transporters .....	12
2.6. Macromolecular and Bulk Transport .....	12
3. Energetics of Membrane Transport .....	12
4. Kinetics of Membrane Transport .....	13
4.1. Kinetic Equation .....	13
4.2. Transport Experiments .....	16
5. Analysis of Membrane Transport .....	18
6. Methods in Membrane Transport Research .....	18
6.1. Patch Clamping .....	19
6.2. Fluorescence Digital Imaging Microscopy .....	20
6.3. Confocal Microscopy .....	21
6.4. Reconstitution .....	21
6.5. Expression in <i>Xenopus laevis</i> Oocytes .....	21
6.6. Cultured Cells .....	22
6.7. Electrophysiological Study of Epithelial Transport .....	23
6.8. Other Commonly Used Experimental Methods .....	24
7. Summary .....	24
References .....	24

## Chapter 2

**Classification of Membrane Transporters***Wolfgang Sadée, Richard C. Graul, and Alan Y. Lee*

1. Introduction .....	29
2. Classification of Transporters by Function and Substrate Specificity ..	30
3. A Genomics View of Transporters .....	32
4. Pharmacogenomics of Transporters .....	35
5. Evolution of Membrane Transporters; Sequence Analysis .....	36
6. Selected Examples of Membrane Transporters .....	39
6.1. H <sup>+</sup> /Dipeptide Symporters .....	40
6.2. Facilitative Glucose Transporters and Related Sequences .....	44
6.3. Sodium/Glucose and Sodium/Nucleoside Cotransporters .....	45
6.4. Amino Acid Transporters .....	48
6.5. Sodium/Neurotransmitter Symporters .....	49
6.6. ATP-Binding Transport Protein Family .....	50
7. Conclusion .....	52
References .....	53

## Chapter 3

**Drug Transport and Targeting: Intestinal Transport***Doo-Man Oh, Hyo-kyung Han, and Gordon L. Amidon*

1. Introduction .....	59
2. Intestinal Transporters .....	60
2.1. General Description of Intestinal Transporters .....	60
2.2. Peptide Transporter .....	64
2.3. Nucleoside Transporter .....	65
2.4. Sugar Transporter .....	66
2.5. Bile Acid Transporter .....	66
2.6. Amino Acid Transporters .....	67
2.7. Organic Anion Transporters .....	67
2.8. Vitamin Transporters .....	68
2.9. Phosphate Transporter .....	68
2.10. Bicarbonate Transporter .....	69
2.11. Organic Cation Transporter .....	69
2.12. Fatty Acid Transporter .....	69
2.13. P-Glycoprotein .....	69

3. Prodrugs: Targeting Intestinal Transporters .....	70
4. Disorders Related to Intestinal Transporters .....	75
4.1. Water and Electrolyte Transporters .....	75
4.2. Sugar Transporters .....	76
4.3. Amino Acid Transporters .....	76
4.4. Bile Acid Transporter .....	76
4.5. Vitamin Transporters .....	77
5. Summary .....	77
References .....	78

## Chapter 4

### The Molecular Basis for Hepatobiliary Transport of Organic Cations and Organic Anions

*Dirk K. F. Meijer, Johan W. Smit, Guido J. E. J. Hooiveld,*

*Jessica E. van Montfoort, Peter L. M. Jansen, and Michael Müller*

1. Introduction .....	89
2. Candidate Proteins for Carrier-Mediated Hepatic Uptake of Cationic Drugs .....	93
3. Candidate Proteins Involved in Bile Canalicular Transport of Cationic Drugs .....	97
3.1. The Cation/Proton Antiport Secretory/Reabsorptive System ...	97
3.2. The <i>mdr1</i> -Type P-Glycoprotein Secretory System .....	99
3.3. Other ABC Transport Proteins in the Canaliculus that May Accommodate Cationic Drugs .....	103
4. Organic Cation Transport in the Intact Liver and Its Short-Term Regulation .....	104
5. Substrate Specificity, Driving Forces, and Multiplicity of Canalicular Organic Cation Carriers .....	105
6. Relation between Chemical Structure and Clearance via Bile, Urine, and Intestine .....	107
7. Molecular Aspects of Organic Cation Transport and Further Perspectives .....	111
8. Hepatic Uptake of Organic Anions: Role of Specific and Polyspecific Transport Proteins .....	112
8.1. $\text{Na}^+$ /Taurocholate Cotransporter (NTCP) .....	113
8.2. Polyspecific Organic Anion Transport Proteins (OATPs) .....	115
9. Transport across the Canalicular Membrane: Role of ABC Transport Proteins .....	116



9.1. MDR3 P-Glycoprotein .....	116
9.2. Homologues of the Multidrug-Resistance Protein MRP1 .....	118
9.3. Canalicular Bile Salt Transporter (cBST/sPgp) .....	120
10. Recent Results from Cholestatic Animal Models .....	121
Appendix: Molecular Features of Currently Identified Carrier Proteins Involved in Sinusoidal Uptake and Canalicular Transport of Organic Cations and Anions .....	122
References .....	140

## Chapter 5

### **Affinity of Drugs to the Different Renal Transporters for Organic Anions and Organic Cations: *In Situ* $K_i$ Values**

*Karl Julius Ullrich*

1. Introduction .....	159
2. Location of the Transport Processes and Transporters in the Proximal Renal Tubule .....	160
3. Transport Processes for Net Reabsorption and Net Secretion .....	162
4. General Information about the $K_i$ Values Given Here .....	169
5. Interaction with Contraluminal PAH Transporter .....	170
6. Interaction with the Contraluminal Sulfate and Dicarboxylate Transporters .....	171
7. Interaction with the Three Organic Cation Transporters .....	171
8. Bi- and Polysubstrates: Drugs which Interact Both with Transporters for Organic Anions and Transporters for Organic Cations .....	172
9. Conclusions and Perspectives .....	173
References .....	173

## Chapter 6

### **Drug Disposition and Targeting: Transport across the Blood–Brain Barrier**

*Bertrand Rochat and Kenneth L. Audus*

1. Introduction .....	181
2. Permeability of the Blood–Brain Barrier .....	183
2.1. Carrier-Mediated Transport .....	183
2.2. Transcytosis .....	190
3. Summary and Future Perspectives .....	193
References .....	193

## Chapter 7

**The Mammalian Facilitative Glucose Transporter (GLUT) Family***Michael J. Seatter and Gwyn W. Gould*

1. Introduction .....	201
2. Background .....	202
3. The Structure of the GLUTs .....	203
3.1. Predicted Secondary Structure of GLUT1 .....	203
3.2. Evidence in Favor of the Secondary Structure Model .....	204
3.3. Biophysical Investigation of GLUT1 .....	204
4. The Dynamics of Glucose Transport .....	205
4.1. The Alternating Conformation Model .....	206
4.2. Oligomerization of GLUT1 .....	208
5. Transporter Photoaffinity Labeling .....	209
6. The Tissue-Specific Distribution of Glucose Transporters .....	211
6.1. GLUT1 .....	211
6.2. GLUT2 .....	212
6.3. GLUT3 .....	216
6.4. GLUT4 .....	218
6.5. GLUT5 .....	219
7. Recent Work and Future Directions .....	220
References .....	221

## Chapter 8

**Cationic Amino Acid Transporters (CATs): Targets for the Manipulation of NO-Synthase Activity?***Ellen I. Closs and Petra Gräf*

1. Introduction .....	229
2. Identification of Four Related Carrier Proteins for Cationic Amino Acids in Mammalian Cells .....	231
2.1. Murine CAT-Proteins (mCATs) .....	231
2.2. Human CAT-Proteins (hCATs) .....	233
3. Transport Properties of the CAT Proteins .....	233
3.1. Substrate Specificity of the mCAT Proteins .....	234
3.2. Kinetics of mCAT-Mediated Transport .....	235
3.3. hCAT-Mediated Transport .....	236
4. CATs and Known Transport Systems for Cationic Amino Acids ....	237
5. Expression of the CAT Proteins in NO-Producing Cells .....	239
6. L-Arginine Transport and NO Synthesis .....	241